Tests a skin cleanser to reduce Staph bacteria in atopic dermatitis
Tests a skin cleanser to lower Staph bacteria in people with atopic dermatitis.
Plain-language title generated from the registry record
Registry title: Effect of S. Aureus Skin Decolonization on Disease Severity in Atopic Dermatitis Patients
Key facts
- Where
- Boston, United StatesSee the site
- Phase
- Phase 4
Where in United States
- Boston Children's HospitalBoston, United StatesNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Boston Children's Hospital
- Trial code
- NCT06397781
- Record updated
- 10 March 2026
- Original description
Our hypothesis is that S. aureus skin decolonization in atopic dermatitis reduces disease severity and favorably alters the function and gene expression of epidermal and immune skin cells that contribute to disease severity.Read full original descriptionShow less
Effect of S. Aureus Skin Decolonization on Disease Severity in Atopic Dermatitis Patients
Our hypothesis is that S. aureus skin decolonization in atopic dermatitis reduces disease severity and favorably alters the function and gene expression of epidermal and immune skin cells that contribute to disease severity.
Inclusion: Male or female participants ≥6 yrs of age; Meet atopic dermatitis Standard Diagnostic Criteria; SCORAD > 40.
Exclusion: Use within 4 weeks of systemic treatment with immunosuppressive/immunomodulating drugs (corticosteroids, cyclosporine, mycophenolate, azathioprine, methotrexate); Treatment with biologics (dupilumab, omalizumab, benralizumab, etc) within sixteen weeks; Use of topical steroids, topical calcineurin inhibitors within 7 days; Asthmatics receiving more than 500 μg per day of inhaled corticosteroids; Hypersensitivity to an agent used for the skin decolonization protocol; History of (HIV, hepatitis B, hepatitis C, tuberculosis malignancy; Severe ongoing medical illnesses e.g. cardiovascular, renal disease, autoimmune disease; Febrile illness at time of visits; Suspected immune deficiency or family history of primary immunodeficiency; . Enrollment in another clinical trial; Phototherapy for AD within 4 weeks; Bleach baths within 7 days of the first Visit; Use of oral or topical antibiotics within 21 days of the beginning of the study; Skin comorbidities that may interfere with assessments: psoriasis, cutaneous T Cell lymphoma,,; Pregnancy.